Overview
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Eligibility
Inclusion Criteria:
- 18 years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
- Signed written informed consent.
Exclusion Criteria:
- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study